Background: Tripartite motif containing 28 (TRIM28) is a transcriptional co-factor targeting many genes with pleiotropic biological activities, but the study on the role of TRIM28 in glioma is rare.
Methods: To explore the function of TRIM28 in glioma, we first detected the expression levels of TRIM28 in glioma tissues and analyzed the correlations of TRIM28 expression with clinicopathological variables of patients in 85 cases of glioma. Meanwhile, we used shRNA to knockdown TRIM28 in glioma cell lines to detect the biological functions of TRIM28 in cell and animal experiments.
Results: We found that TRIM28 was expressed at significantly higher level in glioma tissues than in non-tumor brain, and TRIM28 expression correlated significantly with tumor malignancy. Furthermore, TRIM28 higher expression was also correlated with poor survival of glioma patients (<0.01). Functionally, knockdown of TRIM28 could significantly inhibit cell proliferation and migration in glioma cells. Additionally, we found that TRIM28 could inhibit the expression of E-cadherin significantly by reducing its mRNA stability at the post-transcriptional level.
Conclusion: Our results suggest that TRIM28 overexpression is correlated with glioma malignant progression and patients' poor survival, so targeting TRIM28 could be an efficacious strategy in glioma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188017 | PMC |
| http://dx.doi.org/10.2147/OTT.S168630 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HDAC7 drives glioblastoma to a mesenchymal-like state via LGALS3-mediated crosstalk between cancer cells and macrophages.
Theranostics
December 2024
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan 250012, China.
Article Synopsis
- * The study focuses on the role of HDAC7 in regulating SOX8 expression, which influences the secretion of LGALS3, creating a feedback loop that promotes the aggressive mesenchymal phenotype of GBM and M2 polarization of macrophages.
- * Findings suggest that targeting LGALS3 can enhance the effectiveness of HDAC inhibitors, positioning HDAC7 and LGALS3 as potential new biomarkers and therapeutic targets for GBM treatment.
SOXC Enhances NGN2-Mediated Reprogramming of Glioblastoma Cells Into Neuron-Like Cells by Modulating RhoA and RAC1/CDC42 Pathway Activity.
CNS Neurosci Ther
October 2024
Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Article Synopsis
- Glioblastoma is a common and aggressive brain cancer, and researchers discovered that cancer cells can be transformed into neuron-like cells using specific proteins, NEUROG2 and SOXC.
- The study utilized various techniques, including ChIP-seq and RNA-seq, to explore how NEUROG2 and SOXC factors interact in this reprogramming process, revealing that SOXC factors actually function as transcriptional repressors rather than activators.
- The findings suggest that manipulating pathways involving RhoA and its effectors can mimic the effects of SOXC factors, providing potential new approaches for reprogramming glioblastoma cells into neurons.
, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing mRNA.
Elife
September 2024
Department of Microbiology and Cell Biology, Indian Institute of Science Bangalore, Bangalore, India.
Article Synopsis
- Researchers found a long noncoding RNA called RIM28 that inhibits the tumor suppressor p53 in glioblastoma (GBM) and glioma stem-like cells (GSC), leading to worse cancer outcomes.
- This RNA interacts with a specific mRNA that increases TRIM28 protein, which in turn decreases p53 levels through enhanced ubiquitination, reducing the effectiveness of p53's DNA damage response.
- Silencing RIM28 suppressed GSC growth and reduced glioma tumors, while its overexpression promoted tumor growth and resistance to the chemotherapy drug Temozolomide, suggesting it could be a potential therapeutic target for GBM treatments.
CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3.
Cancers (Basel)
October 2023
CNRS, INSERM, Institut de Biologie Valrose, Team INSERM "Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity", Université Côte D'Azur, 06107 Nice, France.
Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments.
View Article and Find Full Text PDFThe Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.
Cancers (Basel)
November 2022
MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia.
Glioblastoma (GBM) is one of the most aggressive cancers, comprising 60-70% of all gliomas. The large G-protein-coupled receptor family includes cannabinoid receptors CB1, CB2, GPR55, and non-specific ion receptor protein transporters TRPs. First, we found up-regulated , and expression in glioma patient-derived tissue samples and cell lines compared with non-malignant brain samples.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!